Life Sciences Executives Bet on Internal Execution Amid Macro Uncertainty
Event summary
- 62% of life sciences executives report improved confidence in their company outlook, vs. just 9% optimistic about the global economy.
- AI and digital investments are growing at the same rate as R&D, with 71% reporting deployment progress but only 45% seeing measurable gains.
- 61% of leaders cite partnerships as critical for accessing AI capabilities and innovation.
- Biopharma executives prioritize policy and reimbursement risks, while medtech focuses on macroeconomic conditions.
The big picture
Life sciences executives are doubling down on internal execution despite macroeconomic wariness, with AI and partnerships emerging as key levers. The sector's confidence gap—62% company-level vs. 9% global—highlights a strategic pivot toward controllable growth drivers. Success will hinge on translating AI investments into tangible outcomes while navigating divergent risk profiles between biopharma and medtech.
What we're watching
- AI Value Proof
- How life sciences companies will bridge the gap between rapid AI deployment and measurable performance gains.
- Sector-Specific Risks
- Whether biopharma's focus on policy/reimbursement and medtech's emphasis on macro conditions will diverge further in strategy.
- Partnership Dynamics
- The pace at which AI-driven collaborations accelerate innovation pipelines across the industry.